UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate®

Medline ® Abstract for Reference 112

of 'Pathogenesis of hepatic fibrosis'

112
TI
Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis.
AU
Canbay A, Higuchi H, Bronk SF, Taniai M, Sebo TJ, Gores GJ
SO
Gastroenterology. 2002;123(4):1323.
 
BACKGROUND& AIMS: Hepatocyte apoptosis and fibrosis are both features of liver injury. However, the potential mechanistic link between these 2 processes remains obscure. Our aim was to ascertain if Fas-mediated hepatocyte apoptosis promotes liver fibrogenesis during extrahepatic cholestasis.
METHODS: Wild-type and Fas-deficient lymphoproliferation (lpr) mice underwent bile duct ligation. Liver injury was assessed by quantitating hepatocyte apoptosis with the terminal deoxynucleotide transferase-mediated deoxyuridine triphosphate nick-end labeling (TUNEL) assay and determining serum ALT values. mRNA expression was quantitated using real-time polymerase chain reaction technology. Liver fibrosis was assessed by digital image analysis of Sirius red-stained sections.
RESULTS: In 3-day bile duct ligated (BDL) animals, TUNEL-positive hepatocytes and serum ALT values were reduced in lpr versus wild-type animals. Likewise, hepatic mRNA transcripts for alpha-smooth muscle actin and platelet-derived growth factor receptor-beta (initiation phase of stellate cell activation) and transforminggrowth factor beta1 mRNA, collagen 1alpha, and tissue inhibitor of matrix metalloproteinases (perpetuation phase of stellate cell activation) were also reduced in 3-day BDL wild-type mice compared with lpr mice. Finally, in 3-week BDL mice, immunoreactivity for alpha-smooth muscle actin and Sirius red staining for collagen were significantly less in lpr compared with wild-type animals.
CONCLUSION: Fas-mediated hepatocyte injury is mechanistically linked to liver fibrogenesis. These observations suggest that inhibition of Fas-mediated apoptosis may be a therapeutic antifibrogenic strategy in cholestatic liver diseases.
AD
Division of Gastroenterology and Hepatology, Mayo Medical School, Clinic, and Foundation, Rochester, Minnesota 55905, USA.
PMID